Dynamk Capital
Venture capitalNew York · Seed–Series B · 4 people tracked
Investment thesis
Dynamk Capital invests in growth equity and venture capital stages in life sciences and industrial companies. The firm focuses on companies providing technologies, tools, and services for biopharmaceutical discovery, development, and manufacturing, including cell and gene therapies and vaccines.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from public directories
What they invest in
from 3 of 19 portfolio companiesBiotech ×3Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Healthtech ×1
HQs:United States×3United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathFull-stack solution for non-destructive 3D imaging of large tissues at sub-cellular resolution using proprietary chemistry, high-throughput light-sheet microscopy, and cloud-based AI analysis.
Develops analytical testing devices that minimize sample volume requirements for particle count determination in biopharmaceutical analysis.
Enables next-generation cell and gene therapies by efficiently delivering gene-editing payloads while preserving cell function and viability.
Preclinical discovery platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening to accelerate drug discovery.
Elliot Fisher(Cofounder)
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Executive Officer, Director, Promoter)Maria Luisa Pineda(Executive Officer, Director, Promoter)
Provides systems for real-time cellular analysis to accelerate drug discovery and biological research using optical sensors.
Atlanta, US
Samuel Walker Inman(Executive Officer, Director)Dr. Gustavo Mahler(Director)Ian W. Hunter(Executive Officer, Director)
Manufactures handheld cell culture monitors that measure oxygen consumption in multi-well plates for continuous real-time cell analysis.
A stem cell tools and technology company providing standardized platforms to accelerate regenerative medicine development and clinical trials.
BiotechFrederick, US
Jon Rowley(Director)Timothy Kelly(Executive Officer, Director)Margot Connor(Executive Officer, Director)
BoardMartin Westberg(Director)Rob Carlson(Director)Daniella Kranjac(Director)
Provides high-purity mRNA and LNP-mRNA manufacturing services for applications ranging from drug discovery to clinical development.
Develops the Viral Sensitizer platform to reduce production inefficiencies in manufacturing of viral-based therapies, cell therapies, and vaccine candidates.
Designs hardware and AI-driven software platforms for drug screening, primary cell analysis, and cell therapy manufacturing to enhance safety and performance.
Frequently asked questions
- What stage does Dynamk Capital invest at?
- Dynamk Capital invests at the Seed, Series A, Series B stages.
- What sectors does Dynamk Capital focus on?
- Dynamk Capital focuses on Biotech, Medical Devices.
- Where is Dynamk Capital located?
- Dynamk Capital is headquartered in New York, US.
Co-investors · 1
Cota Capital is an investment firm focused on founders building net-new enterprise technology, combining capital with operational expertise, industry insight, competitive intelligence, and a broad network.
Firms observed investing alongside Dynamk Capital, from public investor directories. Shared companies are the overlap with Dynamk Capital's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Fluke Venture Partners is a Pacific Northwest venture firm that has funded technology, healthcare, and consumer companies for over three decades, working with management teams as long-term partners from early stages onward.
Roadmap Capital Inc. is an investment platform providing co-investment access to private companies in technology and healthcare/medtech sectors.